6 results about "Human kidney" patented technology

This invention discloses the application of a reagent that inhibits ADNP gene expression or ADNP protein activity in the preparation of drugs for treating renal fibrosis, belonging to the field of biomedical technology. The application of the reagent that inhibits ADNP gene expression or ADNP protein activity in the preparation of drugs for treating renal fibrosis. This invention effectively knocks down or knocks out the ADNP gene in renal tubular epithelial cells, objectively investigates the effects of ADNP deficiency on a series of phenotypes in HK-2 cells, and confirms that ADNP can inhibit EMT and renal fibrosis in HK-2 cells. Drugs that target and knock down or knock out the ADNP gene in human kidneys can be developed to delay the progression of renal fibrosis.

Provided herein is an adeno-associated virus susceptible cell strain and its application. Specifically, provided herein is an adeno-associated virus susceptible cell strain, and the application of the cell strain. The cell strain is human kidney epithelial cell 293T-AH10 cell with preservation number CCTCC NO: C202331, which moderately and stably expresses three genes of adeno virus (Ad5): E4 gene (Orf6), E2A gene and VARNA gene, and is highly susceptible to adeno-associated virus (AAV) of different serotypes, and can be used for infection titer quantitative test of AAV.

The application belongs to the technical field of biology, and discloses a culture method for large-scale human kidney organoids. The application discloses a culture method for large-scale kidney organoids, which comprises the following steps: using a culture solution to induce culture of stem cells to generate developing organoids; applying fluid shear stress to the developing organoids for culture, i.e. obtaining kidney organoids; the method for applying fluid shear stress comprises placing the developing organoids in a fluid perfusion system, adjusting the fluid flow rate, and making the fluid shear force be 0.02-0.3 dyn / cm 2 , or stirring or rotating a culture system containing the developing organoids. The culture method provided by the application can significantly promote targeted enrichment and maturation of distal renal units, greatly improves the physiological fidelity of the organoids, successfully remodels the metabolic microenvironment, breaks through the glycolysis development bottleneck, and realizes large-scale preparation with high molding rate and high uniformity.

COL3A1 as a marker for detecting kidney stones and its application. The application discloses a new use of COL3A1 as a specific detection marker for kidney stones, and a kit, a detection method and application for detecting kidney stones based on the expression level of COL3A1. Through cross-species transcriptome sequencing, qRT-PCR, Western blot and immunofluorescence verification of human kidney stone clinical samples and mouse kidney stone models, it is confirmed that COL3A1 is significantly up-regulated in kidney tissues of kidney stone lesions, and can be used as a molecular marker for distinguishing kidney stone patients from healthy people. The detection method provided by the application has high specificity and sensitivity, and can realize early screening, auxiliary diagnosis, disease monitoring and recurrence risk assessment of kidney stones, and provides a new molecular target and non-invasive detection scheme for clinical diagnosis of kidney stones.

This invention relates to the fields of regenerative medicine, disease models, and drug screening, and particularly to a high-throughput method and application for constructing human kidney organoids that simulate the pathological characteristics of lupus nephritis. The kidney organoids are mixed and cultured with plasma from lupus nephritis patients in low-adsorption multi-well plates. This invention utilizes a standardized process to prepare human kidney organoids in high throughput, and then stimulates them with plasma from lupus nephritis patients, thereby rapidly and in large quantities constructing disease models in vitro that simulate the severity of individual patients' diseases and reproduce key pathological features (such as podocyte damage and inflammatory fibrosis). This platform provides a closed-loop research tool for lupus nephritis research, from "clinical samples" to "in vitro models" and then to "clinical validation."

The application provides a laminarin proteoglycan purified extract and a preparation method and application thereof. In the preparation process of the purified extract, ultrasonic-assisted water extraction and anion exchange chromatography are used for purification, the extraction efficiency is high, the purification effect is good, the effective components of laminarin proteoglycan in laminaria can be effectively enriched, the obtained extract has high purity and strong activity, the high-value utilization of laminaria resources is realized, the laminarin proteoglycan is extracted and purified as a whole and activity research is conducted, and the synergistic effect is fully exerted. In the application, through the Caenorhabditis elegans model, the zebra fish model and the human kidney epithelial cell (HK-2) model, it is verified that the laminarin proteoglycan purified extract has a significant protection effect on the damage of the organism caused by microplastics, and a new candidate drug and scientific basis are provided for the development of a microplastic damage protection drug.